Deruxtecan analog 2 is a Topo I inhibitor used as a drug-linker conjugate for synthesis of anti-FGFR2 ADC. It is composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with anticancer activity against colorectal, breast, lung and ovarian cancers.
Physicochemical Properties
| Molecular Formula | C29H30FN5O7 |
| Molecular Weight | 579.57621049881 |
| Exact Mass | 579.212 |
| CAS # | 1599440-10-4 |
| PubChem CID | 118305229 |
| Appearance | White to yellow solid powder |
| LogP | -0.9 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 42 |
| Complexity | 1240 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | FC1=CC2=C3C(=C1C)CC[C@@H](C3=C1C(C3=CC4=C(COC([C@@]4(CC)O)=O)C(N3C1)=O)=N2)NC(COCNC(CN)=O)=O |
| InChi Key | DOLQXGLTQNTQEP-SLQAJWMNSA-N |
| InChi Code | InChI=1S/C29H30FN5O7/c1-3-29(40)17-6-21-26-15(9-35(21)27(38)16(17)10-42-28(29)39)25-19(33-23(37)11-41-12-32-22(36)8-31)5-4-14-13(2)18(30)7-20(34-26)24(14)25/h6-7,19,40H,3-5,8-12,31H2,1-2H3,(H,32,36)(H,33,37)/t19-,29-/m0/s1 |
| Chemical Name | 2-amino-N-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methyl]acetamide |
| Synonyms | Deruxtecan analog 2; 1599440-10-4; SCHEMBL17003666; EX-A11383; Exatecan-2-(aminomethoxy)acetamide-Gly; |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage.(2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Topoisomerase; Camptothecins |
| References |
[1]. Anti-FGFR2 antibodies and antibody-drug conjugates methods of use thereof. Patent WO2022087243. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~100 mg/mL (~172.54 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (3.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (3.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7254 mL | 8.6269 mL | 17.2539 mL | |
| 5 mM | 0.3451 mL | 1.7254 mL | 3.4508 mL | |
| 10 mM | 0.1725 mL | 0.8627 mL | 1.7254 mL |